​

 

This seed funding was used to further develop Recōdagen's first-in-class monoclonal antibodies targeting carcinoma-specific Mig7.  

 

Mig7 and our other targets are from our platform strategy that utilizes proprietary knowledge of how previously deemed long "noncoding" RNAs from the dark matter genome do encode proteins.  These genomic transcripts and their proteins tend to be expressed cell- and disease-specifically.

​

Research reported is supported by the National Cancer Institute of the National Institutes of Health under Award Number R43CA235813. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.